12:00 AM
 | 
Apr 03, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

SRL172: Phase II data; Phase III

Final results from SPA's U.K. Phase II trial with SRL172 plus chemotherapy showed a 49 percent survival benefit over chemotherapy alone in 28 patients with small cell...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >